Skip to main content
SpringerLink
Log in

Alectinib/crizotinib

Acquired drug resistance: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zhang C, et al. Efficacy and resistance of ALK inhibitors in two inflammatory myofibroblastic tumor patients with ALK fusions assessed by whole exome and RNA sequencing. OncoTargets and Therapy 13: 10335-10342, 13 Oct 2020. Available from: URL: http://doi.org/10.2147/OTT.S270481

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib/crizotinib. Reactions Weekly 1836, 34 (2021). https://doi.org/10.1007/s40278-021-87853-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-87853-0

Search

Navigation